-
31.发明授权MODIFIED CHIMERIC POLYPEPTIDES WITH IMPROVED PHARMACOKINETIC PROPERTIES 有权具有改进的性质PHARMAKOKYNETISCHEN修饰嵌合多肽
公开(公告)号：EP1183353B1
公开(公告)日：2005-04-13
申请号：EP00932721.4
申请日：2000-05-23
CPC分类号： C07K14/71 , A61K38/00 , C07K2319/00 , C07K2319/30
摘要： Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
-
公开(公告)号：EP1141294B1
公开(公告)日：2005-03-02
申请号：EP99968956.5
申请日：1999-12-23
IPC分类号： C12N15/62 , C12N5/10 , C07K14/515 , C07K14/52
CPC分类号： C07K14/515 , A61K38/00 , C07K14/52 , C07K2319/00 , C07K2319/02 , C07K2319/30 , C07K2319/73 , C07K2319/75 , C12N15/62
摘要： Novel fusion polypeptide ligands that bind Eph family receptors or the Tie-2 receptor are identified, and methods for making the fusion polypeptide ligands in biologically active form are described. Nucleic acids encoding these novel fusion polypeptide ligands enable production of the fusion polypeptide ligands. The method of making the nucleic acids and the fusion polypeptide ligands is broadly applicable to the production of polypeptide ligands in general, resulting in improved affinity and/or increased activity of the ligand when compared to its native form.
-
公开(公告)号：EP0821728B1
公开(公告)日：2004-08-11
申请号：EP96910769.7
申请日：1996-04-05
发明人： DAVIS, Samuel , BRUNO, Joanne , GOLDFARB, Mitchell , ALDRICH, Thomas, H. , MAISONPIERRE, Peter, C. , RADZIEJEWSKI, Czeslaw , JONES, Pamela, F. , YANCOPOULOS, George, D.
CPC分类号： C07K14/515 , A61K38/00
摘要： The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptor body which specifically binds a human TIE-2 ligand. The invention also provides an antibody which specifically binds a human TIE-2 ligand. The invention further provides for an antagonist of human TIE-2. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor, a method of blocking the growth or differentiation of a cell expressing the TIE-2 receptor and a method of attenuating or preventing tumor growth in a human.
-
公开(公告)号：EP1399575A2
公开(公告)日：2004-03-24
申请号：EP01992495.0
申请日：2001-10-31
发明人： ECONOMIDES, Aris, N. , MURPHY, Andrew, J. , VALENZUELA, David, M. , FRENDEWEY, David , YANCOPOULOS, George, D.
IPC分类号： C12N15/90
CPC分类号： A01K67/0275 , A01K2217/05 , A01K2227/105 , C12N15/907
摘要： A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous genes(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.
-
公开(公告)号：EP0651809B1
公开(公告)日：2001-12-05
申请号：EP91912876.9
申请日：1991-06-03
发明人： BOULTON, Teri, G. , COBB, Melanie, H. , YANCOPOULOS, George, D. , NYE, Steven , PANAYOTATOS, Nikos
CPC分类号： G01N33/5041 , C12N9/12 , C12Q1/485 , G01N33/5008 , G01N33/573 , G01N2333/9121 , G01N2500/00
摘要： The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides fore recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity. These methods may be extremely useful in screening compounds for the presence of a desired cellular factor activity. In specific embodiments, compounds which may be useful in the treatment of Alzheimer's disease , peripheral neuropathies, and diabetes may be identified using the methods of the invention.
-
公开(公告)号：EP0915974A1
公开(公告)日：1999-05-19
申请号：EP97937086.0
申请日：1997-08-01
IPC分类号： G01N33 , A61K38 , A61K45 , A61K48 , A61K51 , A61P7 , A61P9 , A61P17 , A61P27 , A61P29 , A61P35 , C07K14 , C07K16 , C07K19 , C12N1 , C12N5 , C12N15 , C12P21
CPC分类号： C12N15/8509 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2227/30 , A01K2267/01 , A01K2267/03 , A01K2267/0331 , A01K2267/0375 , A01K2267/0381 , A61K38/00 , C07K14/515 , C07K14/71 , C07K2319/00 , C07K2319/02
摘要： The present invention provides for a modified TIE-2 ligand which has been altered by addition, deletion or substitution of one or more amino acids, or by way of tagging, with for example, the Fc portion of human IgG-1, but which retains its ability to bind the TIE-2 receptor. The invention further provides for a modified TIE-2 ligand which is a chimeric TIE-2 ligand comprising at least a portion of a first TIE-2 ligand and a portion of a second TIE-2 ligand which is different from the first. In a specific embodiment, the invention further provides for a chimeric TIE ligand comprising at least a portion of TIE-2 Ligand-1 and a portion of TIE-2 Ligand-2. In addition the present invention provides for isolated nucleic acid molecule encoding the modified TIE-2 ligands described. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE receptor, a method of blocking the growth or differentiation of a cell expressing the TIE receptor and a method of attenuating or preventing tumor growth in a human.
-
公开(公告)号：EP0656062A1
公开(公告)日：1995-06-07
申请号：EP93921339.0
申请日：1993-09-02
发明人： VALENZUELA, David, M. , HARLAND, Richard, M. , IP, Nancy, Y. , SMITH, William, C. , YANCOPOULOS, George, D. , CUDNY, Henryk , LAMB, Teresa , KNECHT, Anne
IPC分类号： C12N15 , A61K38 , A61P25 , A61P43 , C07K14 , C07K16 , C12N1 , C12N5 , C12N7 , C12P21 , C12Q1 , A61K39
CPC分类号： C07K16/22 , A61K38/00 , A61K39/00 , C07K14/475
摘要： Novel dorsal growth inducing factors, complexes including the factors, and DNA or RNA coding sequences for the factors are described.
-
公开(公告)号：EP0593663A1
公开(公告)日：1994-04-27
申请号：EP92915861.0
申请日：1992-04-23
CPC分类号： A61K31/70 , A61K31/55 , A61K38/00 , C07K14/475 , C12Q1/68 , C12Q1/6886 , C12Q2600/136 , C12Q2600/142 , G01N33/5011 , A61K2300/00
摘要： Procédé de traitement de tumeurs exprimant la neurotrophine, consistant à interrompre la boucle de survie autocrine par l'administration d'une quantité pharmaceutiquement efficace d'une substance capable d'interrompre ladite boucle autocrine. Des acides nucléiques non codants et du K252a ou ses dérivés, par exemple, peuvent être utilisés dans des compositions pharmaceutiquement acceptables pour interrompre la boucle autocrine d'une cellule tumorale qui dépend de la neurotrophine qu'elle exprime pour sa survie. Un système modèle destiné à identifier d'autres moyens d'interrompre les boucles autocrines est également décrit.
-
公开(公告)号：EP4370210A1
公开(公告)日：2024-05-22
申请号：EP22751556.6
申请日：2022-07-13
-
公开(公告)号：EP3941941A1
公开(公告)日：2022-01-26
申请号：EP20718108.2
申请日：2020-03-20
-
-
-
-
-
-
-
-
-
搜索结果
73 条记录 (耗时 0.042 秒)
